Search Results - ningyan+zhang

7 Results

Sort By:

S100A4 Monoclonal Antibody for Therapeutic and Diagnostic Use

Cancer metastasis are responsible for ~90% of cancer associated deaths. Recent studies suggest that immune cells play critical roles in promoting metastasis, especially myeloid cells from the bone marrow. UTHealth researchers, with researchers from The Methodist Hospital, observed a highly conserved expression of S100A4 in immune suppressive myeloid...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Ningyan Zhang

Keywords(s):

Category(s): Neurology/Neurosurgery, Oncology, Therapeutics

LILRB2 Monoclonal Antibody for Therapeutic and Diagnostic Uses of Neurodegenerative Diseases

Triggering Receptor Expressed on Myeloid cells 2 (TREM2) plays a key regulatory role in Alzheimer’s disease (AD) by controlling microglia activation and metabolic activities in brain tissues. TREM2 signaling inhibition is mediated by leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2). UTHealth inventors created and engineered...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Ningyan Zhang

Keywords(s):

Category(s): Neurology/Neurosurgery, Therapeutics

Antibodies against CD5L for therapeutic and diagnostic uses

Provided herein are anti-CD5L monoclonal antibodies. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer. UTHealth Ref. No.: 2020-0016 Inventors: Dr. Zhiqiang An and Dr. Ningyan Zhang at UTHealth; Dr. Anil Sood at UT M.D. Anderson Cancer Center Patent Status: PCT application PCT/US2021/025429...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Ningyan Zhang, Anil Sood

Keywords(s):

Category(s): Biologics, Oncology, Therapeutics

Monoclonal Antibodies Against PCDH7 for Therapeutic and Diagnostic Use

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-associated deaths worldwide. UTHealth researchers discovered that the cell surface protein Protocadherin 7 (PCDH7) is highly expressed in NSCLC and promotes lung cancer development. Inventors at UTH in collaboration with Dr. O’Donnell’s group at UTSW have discovered a panel...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Ningyan Zhang, Kathryn O'Donnell

Keywords(s):

Category(s): Diagnostics, Oncology, Therapeutics, Biologics

Monoclonal antibodies against human endotrophin for therapeutic and diagnostic use.

Background Studies have shown that endotrophin, the carboxy-terminal cleavage product of the COL6α3 chain, has potent effects on transformed mammary ductal epithelial cells in rodents. It is abundantly expressed in adipose tissue and is a chemoattractant for macrophages, exerts effects on endothelial cells and enhances the progression through...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Ningyan Zhang, Philipp Scherer

Keywords(s):

Category(s): Biologics, Oncology, Therapeutics

Monoclonal antibodies against human and mouse leptin for therapeutic and diagnostic use.

BackgroundLeptin is a hormone produced by adipocytes and is elevated in obesity. The congenital lack of leptin results in obesity and the metabolism field widely accepts the concept. Upon cloning of the leptin gene, the original hope was that leptin would act as a break for further food intake and a trigger to increase energy expenditure. The hope was...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Philipp Scherer, Ningyan Zhang

Keywords(s):

Category(s): Biologics, Oncology, Therapeutics, Metabolism

HER3 specific monoclonal antibodies for diagnosis and therapeutic use

BackgroundHER-3 is a receptor in the tyrosine kinase family that is a key oncogenic protein in breast cancer as well as other cancers. HER-3 is centrally involved in signaling leading to tumor growth and has been implicated in resistance to cancer treatments, making it an attractive target for cancer therapies. Several drugs, including some in clinical...

Published: 10/21/2024 | Inventor(s): Zhiqiang An, Ningyan Zhang

Keywords(s):

Category(s): Therapeutics, Diagnostics, Biologics, Oncology